Altavilla D, Bitto A, Polito F, Irrera N, Marini H, Arena S, Favilla V, Squadrito F, Morgia G, Minutoli L. The combination of Serenoa repens, selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth. J Urol. 2011;186(4):1524-9.
Arias-Santiago S, Arrabal-Polo MA, Buendia-Eisman A, et al. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J Am Acad Dermatol. 2012;66(3):401-8.
Avins AL, Lee JY, Meyers CM, Barry MJ. Safety and Toxicity of saw palmetto in the CAMUS trial. J Urol. 2013;189(4):1415-20.
Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullogh A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT: Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-51.
Bechis SK, Ostetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192(1):16-23.
Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85:842-6.
Bondarenko B, Walther C, Funk P, Schlafke S, Engelmann U. Long-term efficacy and safety of PRO 160/120 (a combination of sabal and urtica extract) in patients with lower urinary tract symptoms (LUTS). Phytomedicine. 2003:10 Suppl 4:53-55.
Bope & Kellerman: Conn's Current Therapy 2013. 1st ed. Philadelphia, PA: Elsevier Saunders; 2012.
Boy S, Seif C, Braun PM, Junemann KP. Botulinum toxin in the treatment of benign prostatic hyperplasia: an overview. Urologe A. 2008;47(11):1465-71.
Chapple CR. Clinical study of benign prostatic disease, current concepts and future prospects randomized controlled trials versus real life practice. Curr Opin Urol. 2003;13(1):1-5.
Delongchamps N, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP. Evaluation of prostatitis in autopsied prostates -- is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol. 2008;179(5):1736-40.
Edwards J. Diagnosis and Management of Benign Prostatic Hyperplasia. American Family Physician. 2008;77(10).
Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42-53.
Ferri: Ferri's Clinical Advisor 2016. 1st ed. Philadelphia, PA: Elsevier Saunders; 2015.
Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828-34.
Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower unrinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(4):CD007360.
Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 2000;163(5):1408-12.
Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58(6):960-5.
Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the porostate: results at 7 years. BJU Int. 2011 Aug 32. [Epub ahead of print]
Gonzales GF. Ethnobiology and ethnopharmacology of lepidum meyenii (maca), a plant from the Peruvian highlands. Evid Based Complement Alternat Med. 2011 Oct 2. [Epub ahead of print]
Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67(6):1281-3.
Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systemic review. Maturitas. 2012;72(4):269-76.
Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000;109:654-64.
Kane CJ, Raheem OA, Bent S, Avins AL. What do I tell patients about saw palmetto for benign prostatic hyperplasia? Urol Clin North Am. 2011;38(3):261-77.
Katz AE. Flavonoid and botanical approaches to prostate health. J Altern Complemet Med. 2002;8(6):813-21.
Klingler HC. New innovative therapies for benign prostatic hyperplasia: any advance? Curr Opin Urol. 2003;13(1):11-15.
Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med. 2001;67(6):489-500.
Kosalec I, Kopjar N, Kremer D. Antimicrobial activity of Willowherb (Epilobium angustifolium L.) leaves and flowers. Curr Drug Targets. 2013;14(9):986-91.
MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85:836-41.
Managing lower urinary tract symptoms in men. Drug Ther Bull. 2003;41(3):18-21.
Marks LS, Partin AW, Epstein JI, et al. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163(5):1451-6.
Mazur D, Helfand B, McVary K. Influences of Neuroregulatory Factors on the Development of Lower Urinary Tract Symptoms/ Benign Prostatic Hyperplasia and Erectile Dysfunction in Aging Men. Urologic Clinics of North America. Philadelphia, PA: W.B. Saunders Company. 2012;39(1).
Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgrad Med. 2015:127(3):301-7.
Na Y, Ye Z, Zhang S. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: A randomized, double-blind, parallel-group, placebo-controlled study with an open-lable extension. Clic Drug Investig. 2011 Oct 21. [Epub ahead of print]
Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009;181(5):2214-21.
Parsons JK, Sarma AV, Mcvary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189(1 Suppl):S102-6.
Penson DF, Munro HM, Signorello LB, Blot WJ, Fowke JH; Urologic diseases in America project. Obesity, physical activity and lower urinary tract symptoms: results from the southern community cohort study. J Urol. 2011;186(6):2316-22.
Pinheiro LC, Martins Pisco J. Treatment of benign prostatic hyperplasia. Tech Vasc Interv Radiol. 2012;15(4):256-60.
Pinto JD, He HG, Chan SW, Toh PC, Esuvaranathan K, Wang W. Health-related quality of life and psychological well-being in patients with benign prostatic hyperplasia. J Clin Nurs. 2015;24(3-4):511-22.
Pittler MH. Complementary therapies for treating benign prostatic hyperplasia. FACT. 2000;5(4):255-7.
Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60(5):1105-13.
Rotblatt M, Ziment I. Evidence-Based Herbal Medicine. Philadelphia, PA: Hanley & Belfus, Inc.; 2002:327-31.
Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A, Rao J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J Urol. 2008;179(2):610-5.
Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche B. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int. 2011;86(3):248-9.
Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr. 2002;75(4):689-97.
Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(2):CD001423.
Willets KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int. 2003;92(3):267-70.
Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;CD001044.
Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(3):CD001423
Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000;3(4A):459-72.